Montana G S, Thomas G M, Moore D H, Saxer A, Mangan C E, Lentz S S, Averette H E
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1007-13. doi: 10.1016/s0360-3016(00)00762-8.
To determine if patients with carcinoma of the vulva, with N2/N3 lymph nodes, could undergo resection of the lymph nodes and primary tumor following preoperative chemo-radiation. METHODS AND MATERILAS: Fifty-two patients were entered in the study, but six patients did not meet the criteria of the protocol and were excluded. The remaining 46 patients are the subject of this report. Patients underwent a split course of radiation, 4760 cGy to the primary and lymph nodes, with concurrent chemotherapy, cisplatin/5-FU, followed by surgery.
Four patients did not complete the chemo-radiation, because three expired and one refused to complete the treatment. Four patients who completed chemo-radiation did not undergo surgery, because two of them died of non-cancer-related causes, and in the other two patients, the nodes remained unresectable. Following chemo-radiation, the disease in the lymph nodes became resectable in 38/40 patients. Two patients who completed the course of chemo-radiation did not undergo surgery as per protocol because of pulmonary metastasis. One underwent radical vulvectomy and unilateral node dissection and the other radical vulvectomy only. The specimen of the lymph nodes was histologically negative in 15/37 patients. Nineteen patients developed recurrent and/or metastatic disease. The sites of failure were as follows: primary area only, 9; lymph node area only, 1; primary area and distant metastasis, 1; distant metastasis only, 8. Local control of the disease in the lymph nodes was achieved in 36/37 and in the primary area in 29/38 of the patients. Twenty patients are alive and disease-free, and five have expired without evidence of recurrence or metastasis. Two patients died of treatment-related complications.
High resectability and local control rates of the lymph nodes were obtained in patients with carcinoma of the vulva with N2/N3 nodes treated preoperatively with chemo-radiation.
确定患有外阴癌且伴有N2/N3淋巴结转移的患者在术前放化疗后能否进行淋巴结及原发肿瘤切除术。方法与材料:52例患者进入本研究,但6例患者不符合方案标准而被排除。其余46例患者为本报告的研究对象。患者接受分程放疗,原发灶及淋巴结剂量为4760 cGy,同时给予顺铂/5-氟尿嘧啶化疗,随后进行手术。
4例患者未完成放化疗,其中3例死亡,1例拒绝完成治疗。4例完成放化疗的患者未接受手术,2例死于非癌症相关原因,另外2例患者的淋巴结仍无法切除。放化疗后,40例患者中有38例的淋巴结疾病变得可切除。2例完成放化疗疗程的患者因肺转移未按方案接受手术。1例接受了根治性外阴切除术及单侧淋巴结清扫术,另1例仅接受了根治性外阴切除术。37例患者中15例淋巴结标本组织学检查为阴性。19例患者出现复发和/或转移疾病。失败部位如下:仅原发灶区域,9例;仅淋巴结区域,1例;原发灶区域及远处转移,1例;仅远处转移,8例。37例患者中有36例实现了淋巴结疾病的局部控制,38例患者中有29例实现了原发灶区域的局部控制。20例患者存活且无疾病,5例患者死亡,无复发或转移迹象。2例患者死于治疗相关并发症。
术前接受放化疗的伴有N2/N3淋巴结转移的外阴癌患者,淋巴结具有较高的可切除率和局部控制率。